Thermo Fisher Scientific - TMO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $656.56
  • Forecasted Upside: 29.08 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$508.66
▼ -5.65 (-1.10%)

This chart shows the closing price for TMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Thermo Fisher Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMO

Analyst Price Target is $656.56
▲ +29.08% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Thermo Fisher Scientific in the last 3 months. The average price target is $656.56, with a high forecast of $718.00 and a low forecast of $525.00. The average price target represents a 29.08% upside from the last price of $508.66.

This chart shows the closing price for TMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Thermo Fisher Scientific. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/5/2021
  • 1 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/4/2021
  • 1 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/2/2021
  • 1 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/31/2021
  • 1 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/31/2022
  • 1 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/29/2022
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/28/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2022BarclaysLower TargetOverweight$685.00 ➝ $595.00Low
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$675.00Low
8/9/2022BarclaysBoost Target$685.00Low
8/1/2022BarclaysBoost TargetOverweight$630.00 ➝ $685.00Low
7/29/2022Morgan StanleyBoost TargetOverweight$670.00 ➝ $678.00Low
7/29/2022SVB LeerinkBoost TargetOutperform$630.00 ➝ $650.00Low
7/13/2022BarclaysLower TargetOverweight$675.00 ➝ $630.00N/A
4/25/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$605.00 ➝ $525.00Medium
2/3/2022BTIG ResearchReiterated RatingBuy$718.00Low
2/3/2022Wells Fargo & CompanyLower TargetEqual Weight$700.00 ➝ $605.00Low
1/26/2022BarclaysInitiated CoverageOverweight ➝ Overweight$700.00Medium
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$625.00 ➝ $700.00High
10/28/2021Morgan StanleyInitiated CoverageOverweightMedium
10/28/2021Robert W. BairdBoost TargetOutperform$635.00 ➝ $657.00Medium
10/28/2021CitigroupBoost TargetBuy$700.00 ➝ $715.00Medium
10/28/2021SVB LeerinkBoost TargetOutperform ➝ Outperform$675.00 ➝ $685.00Medium
10/20/2021CitigroupUpgradeNeutral ➝ Buy$620.00 ➝ $700.00Medium
10/14/2021CowenBoost TargetOutperform$655.00 ➝ $696.00Medium
9/23/2021The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
9/23/2021CowenBoost TargetOutperform$560.00 ➝ $655.00Low
9/22/2021BenchmarkBoost TargetPositive ➝ Buy$580.00 ➝ $650.00Medium
9/22/2021BTIG ResearchBoost TargetBuy$610.00 ➝ $700.00Medium
9/21/2021UBS GroupBoost TargetBuy$595.00 ➝ $670.00Low
9/20/2021Jefferies Financial GroupInitiated CoverageHold$540.00High
9/20/2021SVB LeerinkBoost TargetOutperform$600.00 ➝ $675.00Medium
9/20/2021KeyCorpBoost TargetOverweight$555.00 ➝ $710.00Low
9/20/2021JPMorgan Chase & Co.Boost TargetOverweight$600.00 ➝ $700.00Low
9/20/2021CitigroupBoost TargetNeutral$535.00 ➝ $620.00Low
8/4/2021ArgusBoost TargetAverage ➝ Buy$530.00 ➝ $600.00Low
7/29/2021CowenBoost TargetOutperform$525.00 ➝ $560.00Low
7/29/2021BTIG ResearchBoost TargetBuy$590.00 ➝ $610.00Low
7/19/2021SVB LeerinkReiterated RatingOutperformLow
7/16/2021BenchmarkInitiated CoverageBuy$580.00Medium
7/12/2021KeyCorpBoost TargetOverweight$520.00 ➝ $555.00Low
6/23/2021Robert W. BairdBoost TargetPositive ➝ Outperform$545.00 ➝ $550.00Low
6/15/2021The Goldman Sachs GroupLower TargetBuy$590.00 ➝ $530.00Low
5/3/2021Robert W. BairdReiterated RatingBuyLow
4/16/2021Evercore ISIBoost TargetOutperform$525.00 ➝ $540.00Low
3/29/2021UBS GroupLower TargetBuy$588.00 ➝ $560.00Low
3/18/2021KeyCorpUpgradeSector Weight ➝ Overweight$520.00Low
3/8/2021BarclaysInitiated CoverageOverweight$525.00N/A
3/2/2021BarclaysInitiated CoverageOverweight$525.00Medium
2/3/2021BTIG ResearchBoost TargetBuy$540.00 ➝ $590.00High
2/2/2021CitigroupBoost TargetBuy$500.00 ➝ $530.00Low
2/2/2021Stifel NicolausBoost TargetBuy$530.00 ➝ $600.00Low
2/2/2021CowenBoost TargetOutperform$525.00 ➝ $585.00Low
2/2/2021Morgan StanleyBoost TargetOverweight$535.00 ➝ $575.00Low
2/2/2021UBS GroupBoost TargetPositive ➝ Buy$566.00 ➝ $588.00Low
2/2/2021SVB LeerinkBoost TargetOutperform$525.00 ➝ $560.00Low
1/12/2021Credit Suisse GroupBoost Target$556.00 ➝ $580.00High
1/8/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$490.00 ➝ $556.00Medium
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralHigh
12/2/2020Credit Suisse GroupBoost TargetNeutral$488.00 ➝ $490.00Low
12/2/2020Robert W. BairdBoost TargetOutperform$512.00 ➝ $523.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$570.00Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$550.00High
10/27/2020Needham & Company LLCBoost TargetBuy$477.00 ➝ $539.00Low
10/22/2020BTIG ResearchBoost TargetPositive ➝ Buy$475.00 ➝ $540.00High
10/22/2020Robert W. BairdBoost TargetOutperform$481.00 ➝ $512.00High
10/22/2020Credit Suisse GroupBoost TargetNeutral$432.00 ➝ $488.00High
10/22/2020Morgan StanleyBoost TargetOverweight$485.00 ➝ $535.00High
10/22/2020SVB LeerinkBoost TargetOutperform$470.00 ➝ $525.00High
10/5/2020JPMorgan Chase & Co.Boost TargetOverweight$460.00 ➝ $480.00High
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$494.00Medium
9/17/2020Needham & Company LLCBoost TargetBuy$468.00 ➝ $477.00Low
9/14/2020Morgan StanleyInitiated CoverageOverweight$485.00Low
9/11/2020Bank of AmericaBoost TargetBuy$460.00 ➝ $480.00Low
9/11/2020Credit Suisse GroupBoost TargetNeutral$425.00 ➝ $432.00Low
9/11/2020SVB LeerinkBoost TargetOutperform$455.00 ➝ $470.00Medium
9/11/2020CitigroupBoost TargetBuy$471.00 ➝ $485.00Medium
8/21/2020Credit Suisse GroupBoost TargetNeutral$405.00 ➝ $425.00Medium
8/20/2020JPMorgan Chase & Co.Reiterated RatingOverweight$460.00Low
8/13/2020Needham & Company LLCInitiated CoverageBuy$468.00Low
7/27/2020ArgusBoost Target$370.00 ➝ $450.00Low
7/23/2020Robert W. BairdBoost Target$352.00 ➝ $436.00Low
7/23/2020Needham & Company LLCBoost TargetBuy$415.00 ➝ $468.00Low
7/23/2020BTIG ResearchBoost TargetBuy$372.00 ➝ $475.00Low
7/23/2020CitigroupBoost TargetBuy$390.00 ➝ $471.00Low
7/23/2020Stifel NicolausBoost TargetHold ➝ Buy$370.00 ➝ $460.00Low
7/23/2020SVB LeerinkBoost TargetOutperform$365.00 ➝ $455.00Low
7/21/2020UBS GroupBoost TargetBuy$385.00 ➝ $440.00High
7/7/2020Needham & Company LLCBoost TargetBuy$383.00 ➝ $415.00Low
7/6/2020CowenReiterated RatingBuy$380.00Low
4/23/2020CitigroupBoost TargetBuy$365.00 ➝ $390.00High
4/23/2020SVB LeerinkBoost TargetOutperform$330.00 ➝ $365.00High
4/23/2020Needham & Company LLCBoost Target$341.00 ➝ $383.00High
4/22/2020Needham & Company LLCBoost TargetBuy$341.00 ➝ $383.00Medium
4/21/2020Wells Fargo & CompanyBoost TargetEqual Weight$300.00 ➝ $340.00High
4/2/2020Stifel NicolausLower TargetBuy$345.00 ➝ $315.00Medium
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$345.00 ➝ $300.00Medium
3/20/2020CitigroupLower TargetBuy$390.00 ➝ $365.00Low
3/4/2020Robert W. BairdBoost TargetOutperform$340.00 ➝ $341.00High
2/24/2020ArgusReiterated RatingBuy ➝ Positive$370.00High
1/31/2020BTIG ResearchBoost TargetBuy ➝ In-Line$342.00 ➝ $372.00High
1/31/2020Robert W. BairdBoost TargetOutperform$319.00 ➝ $340.00High
1/31/2020Wells Fargo & CompanyLower TargetEqual Weight$350.00 ➝ $345.00High
1/31/2020Needham & Company LLCBoost TargetBuy$331.00 ➝ $341.00High
1/31/2020CitigroupBoost TargetBuy$380.00 ➝ $390.00High
1/22/2020Credit Suisse GroupInitiated CoverageNeutral$341.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$350.00Low
1/6/2020CitigroupInitiated CoverageBuy$380.00Low
1/6/2020CowenReiterated RatingOutperform$330.00 ➝ $365.00Medium
1/3/2020Needham & Company LLCInitiated CoverageStrong-Buy$271.00Medium
11/14/2019Stifel NicolausInitiated CoverageBuy$345.00Medium
11/14/2019Evercore ISIUpgradeOutperformHigh
10/24/2019Robert W. BairdBoost TargetOutperform$305.00 ➝ $319.00Low
10/23/2019JPMorgan Chase & Co.Boost TargetOverweight$315.00 ➝ $330.00Low
7/31/2019Credit Suisse GroupReiterated RatingBuy$310.00Low
7/25/2019Needham & Company LLCBoost TargetBuy ➝ Buy$315.00 ➝ $321.00Low
7/16/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$315.00Low
7/15/2019BarclaysSet TargetBuy$330.00Medium
5/30/2019Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
5/23/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$313.00 ➝ $315.00Low
5/23/2019BTIG ResearchBoost TargetAverage ➝ Buy$320.00Low
5/23/2019UBS GroupBoost TargetBuy$305.00 ➝ $320.00Low
5/1/2019ArgusBoost TargetBuy ➝ Buy$285.00 ➝ $310.00Low
4/22/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$271.00 ➝ $312.00Low
4/16/2019Bank of AmericaReiterated RatingBuy ➝ Buy$285.00 ➝ $300.00High
3/26/2019Robert W. BairdBoost TargetOutperform ➝ Outperform$270.00 ➝ $288.00Low
3/26/2019BTIG ResearchBoost TargetBuy$310.00Low
3/25/2019UBS GroupBoost TargetBuy$305.00High
3/22/2019Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$275.00 ➝ $300.00High
3/18/2019BarclaysBoost TargetOverweight ➝ Overweight$295.00 ➝ $300.00Low
1/31/2019BTIG ResearchBoost TargetBuy$290.00Medium
1/30/2019Robert W. BairdBoost TargetOutperform$264.00 ➝ $270.00Low
1/3/2019BarclaysBoost TargetOverweight ➝ Overweight$275.00 ➝ $280.00Low
1/2/2019Needham & Company LLCInitiated CoverageStrong-Buy ➝ Strong-Buy$271.00High
10/25/2018Morgan StanleyBoost TargetOverweight$254.00 ➝ $260.00Low
10/25/2018Robert W. BairdBoost TargetOutperform$256.00 ➝ $264.00Low
10/10/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$242.00 ➝ $254.00High
10/10/2018CitigroupBoost TargetBuy ➝ Buy$260.00 ➝ $280.00High
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$295.00Low
9/24/2018BarclaysBoost TargetOverweight ➝ Overweight$250.00 ➝ $275.00Low
9/17/2018The Goldman Sachs GroupDowngradeBuy ➝ NeutralMedium
7/26/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$233.00 ➝ $242.00Low
7/26/2018SVB LeerinkBoost TargetOutperform$239.00 ➝ $255.00Medium
7/26/2018JPMorgan Chase & Co.Reiterated RatingOverweight$300.00Medium
7/13/2018Morgan StanleyBoost TargetOverweight$230.00 ➝ $233.00Low
4/26/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$216.00 ➝ $230.00Low
4/11/2018Morgan StanleyLower TargetOverweight ➝ Overweight$228.00 ➝ $216.00Low
2/1/2018Bank of AmericaBoost TargetBuy ➝ Buy$235.00 ➝ $250.00Low
2/1/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$223.00 ➝ $227.00Low
2/1/2018BarclaysBoost TargetOverweight ➝ Overweight$225.00 ➝ $245.00Low
2/1/2018SVB LeerinkReiterated RatingOutperform$200.00 ➝ $239.00Low
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$230.00Medium
1/3/2018Evercore ISIInitiated CoverageOutperform$220.00Medium
12/4/2017SVB LeerinkReiterated RatingOutperform$216.00 ➝ $200.00High
10/30/2017SVB LeerinkReiterated RatingBuyN/A
10/26/2017Deutsche Bank AktiengesellschaftSet TargetBuy$216.00 ➝ $226.00N/A
10/9/2017SVB LeerinkBoost TargetOutperform$190.00 ➝ $207.00N/A
9/28/2017Jefferies Financial GroupReiterated RatingHold$195.00Low
(Data available from 9/27/2017 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 51 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
3/1/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/31/2022
  • 7 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/30/2022
  • 4 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/29/2022
  • 4 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/29/2022
  • 8 very positive mentions
  • 39 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/27/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Thermo Fisher Scientific logo
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $508.66
Low: $505.58
High: $518.20

50 Day Range

MA: $566.54
Low: $508.66
High: $604.49

52 Week Range

Now: $508.66
Low: $497.83
High: $672.34

Volume

1,152,879 shs

Average Volume

1,427,879 shs

Market Capitalization

$199.29 billion

P/E Ratio

27.07

Dividend Yield

0.23%

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Thermo Fisher Scientific?

The following Wall Street analysts have issued stock ratings on Thermo Fisher Scientific in the last year: Barclays PLC, BTIG Research, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Morgan Stanley, Robert W. Baird, StockNews.com, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for TMO.

What is the current price target for Thermo Fisher Scientific?

9 Wall Street analysts have set twelve-month price targets for Thermo Fisher Scientific in the last year. Their average twelve-month price target is $656.56, suggesting a possible upside of 29.1%. BTIG Research has the highest price target set, predicting TMO will reach $718.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $525.00 for Thermo Fisher Scientific in the next year.
View the latest price targets for TMO.

What is the current consensus analyst rating for Thermo Fisher Scientific?

Thermo Fisher Scientific currently has 1 sell rating, 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TMO will outperform the market and that investors should add to their positions of Thermo Fisher Scientific.
View the latest ratings for TMO.

What other companies compete with Thermo Fisher Scientific?

How do I contact Thermo Fisher Scientific's investor relations team?

Thermo Fisher Scientific's physical mailing address is 168 Third Avenue, Waltham MA, 02451. The medical research company's listed phone number is (781) 622-1000 and its investor relations email address is [email protected] The official website for Thermo Fisher Scientific is www.thermofisher.com. Learn More about contacing Thermo Fisher Scientific investor relations.